Article
Hematology
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Summary: Autologous stem cell transplantation (ASCT) following anti-PD-1 therapy shows promising outcomes for relapsed/refractory Hodgkin lymphoma (HL) patients, even in high-risk cases, with favorable survival rates observed.
Article
Hematology
Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J. Deyell, Jamie E. Flerlage, Anna K. Franklin, Jennifer Krajewski, Kasey J. Leger, Lianna J. Marks, Robin E. Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul D. Harker-Murray, Lisa Giulino-Roth
Summary: Through a retrospective analysis of 67 pediatric patients, it was found that brentuximab vedotin in combination with vedotin had good tolerability and a safety profile similar to that of adult patients in the treatment of relapsed/refractory Hodgkin lymphoma. With a median follow-up of 37 months, the 3-year progression-free survival was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in children with relapsed/refractory Hodgkin lymphoma.
Article
Hematology
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera
Summary: This study evaluated the combination of BV and Nivo as first salvage therapy for r/r cHL patients, showing high objective response rate and progression-free survival without additional toxicity concerns. Some patients were able to directly proceed to transplant after study treatment, indicating durable efficacy and impressive outcomes.
Article
Hematology
Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael J. Absalon, Sharon M. Castellino, Anna Franklin, Frank G. Keller, Neerav Shukla
Summary: In this study, BVB was found to be well tolerated in pediatric patients with R/R HL and compared favorably with currently accepted salvage regimens, showing promising efficacy and outcomes in this population.
Article
Hematology
Sanjal H. Desai, Michael A. Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, Vaishalee P. Kenkre, Sally Arai, Cheryl Chang, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse Harris, Harsh Shah, Jacob Murphy, Stephen Ansell, Deepa Jagadish, Victor Orellana-noia, Catherine Diefenbach, Siddharth Iyenger, K. C. Rappazzo, Rahul Mishra, Yun Choi, Grzegorz S. Nowakowski, Ranjana H. Advani, Ivana N. Micallef
Summary: This multicenter retrospective study found that salvage therapies with checkpoint inhibitor (CPI)-based regimens had superior event-free survival (EFS) and progression-free survival (PFS) compared to conventional chemotherapy and other salvage regimens, supporting the use of CPI-based regimens in relapsed/refractory transplant-eligible classic Hodgkin lymphoma (R/R cHL) in the pre-autologous stem cell transplant (ASCT) setting.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Article
Hematology
A. Marouf, N. Molinari, D. Sibon, A. S. Cottereau, S. Kanoun, C. Antoine, P. E. Debureaux, D. Cavalieri, L. M. Fornecker, R. O. Casasnovas, C. Herbaux, S. Amorim, C. Rossi, D. Bouscary, P. Brice, H. Ghesquieres, J. Tamburini, B. Deau
Summary: Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for high-risk relapsed/refractory Hodgkin lymphoma (R/R HL) patients. Maintenance therapy with Brentuximab Vedotin (BV) after ASCT has been shown to improve survival in BV-naive patients. In this study, BV maintenance was compared to tandem transplant strategies and was found to be associated with better survival outcomes in patients with high-risk R/R HL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Julia Driessen, Gerben J. C. Zwezerijnen, Heiko Schoeder, Marie Jose Kersten, Alison J. Moskowitz, Craig H. Moskowitz, Jakoba J. Eertink, Martijn W. Heymans, Ronald Boellaard, Josee M. Zijlstra
Summary: We developed a prognostic model for progression-free survival (PFS) in patients with relapsed or primary refractory classical Hodgkin lymphoma (R/R cHL) using baseline quantitative F-18-fluorodeoxyglucose positron emission tomography (PET) radiomics features and clinical characteristics. The model can help predict PFS outcomes and guide risk-stratified treatment strategies for R/R cHL patients.
Article
Oncology
Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Summary: This study evaluated the outcomes of single or tandem ASCT in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL), especially in high-risk patients. The results showed that tandem transplantation can significantly improve the progression-free survival rate in high-risk patients, but there was no significant difference in overall survival rate.
Article
Oncology
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Summary: Achieving minimal disease status before autologous stem cell transplantation (ASCT) is crucial for Hodgkin lymphoma (HL) patients. This retrospective study evaluated the effectiveness and safety of the BEGEV regimen as a first salvage treatment prior to ASCT in HL patients. The results showed that the BEGEV regimen was able to induce complete response in a significant number of patients with limited toxicity, and did not impair peripheral blood stem cell mobilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Paolo Strati, Phoebe T. M. Cheng, Raphael E. Steiner, Pedro E. Alcedo Andrade, Lei Feng, Dahlia Sano, Veeramaneni A. Rao, Prachee Singh, Roberto Miranda, Jillian R. Gunther, Chelsea C. Pinnix, Bouthaina S. Dabaja, Branko Cuglievan, Katharine Xing, Diego Villa, Brian Skinnider, Laurie H. Sehn, Joseph M. Connors, Yago Nieto, Sairah Ahmed, Hun J. Lee, Kerry J. Savage
Summary: NLPHL patients with relapsed or progressive disease after initial treatment showed a median progression-free survival of four years after front-line treatment, with chemotherapy, biological therapy, stem cell transplant, and radiation therapy being common second-line treatments. Despite the good five-year progression-free survival rate of 68% after second-line therapy, the overall survival remained excellent at 94%. Further studies are needed to understand the biology of NLPHL and guide therapy de-escalation.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Health Care Sciences & Services
Jeremy A. Meier, Barbara Savoldo, Natalie S. Grover
Summary: Treatment for Hodgkin lymphoma has advanced significantly, but a portion of patients still experience relapse or disease progression. Immunotherapies, particularly CAR T cells, have shown exceptional promise in treating relapsed/refractory HL.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Fulvio Massaro, Nathalie Meuleman, Dominique Bron, Marie Vercruyssen, Marie Maerevoet
Summary: This retrospective study evaluated the efficacy of a combination of brentuximab vedotin and pembrolizumab as a bridge treatment to autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (HL) patients. The results showed that this combination therapy is highly effective for high-risk patients.
Article
Oncology
Colton Ladbury, Swetha Kambhampati, Tamer Othman, Claire Hao, Lu Chen, Jeffrey Wong, Thai Cao, Alex Herrera, Matthew Mei, Savita Dandapani
Summary: Approximately 50% of patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) will relapse post-autologous stem cell transplant (ASCT). This study investigated the use of radiation therapy (RT) as salvage treatment for these patients. The results showed favorable oncologic outcomes for patients who received RT as first salvage therapy post-ASCT, particularly those with localized disease.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Hematology
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Summary: The study demonstrates favorable outcomes for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma treated with the selective Bruton's tyrosine kinase inhibitor zanubrutinib. The results support zanubrutinib as a potentially meaningful addition to available therapies for these patients.
Article
Hematology
Panayotis Kaloyannidis, Mark Hertzberg, Kate Webb, Athanasios Zomas, Rudolf Schrover, Michael Hurst, Ian Jacob, Thalia Nikoglou, Joseph M. Connors
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Biochemical Research Methods
Michael D. Nissen, Manabu Kusakabe, Xuehai Wang, Guillermo Simkin, Deanne Gracias, Kateryna Tyshchenko, Ainsleigh Hill, Justin Meskas, Stacy Hung, Elizabeth A. Chavez, Daisuke Ennishi, Tomohiro Aoki, Clementine Sarkozy, Joseph M. Connors, Pedro Farinha, Graham W. Slack, Randy D. Gascoyne, Ryan R. Brinkman, David W. Scott, Christian Steidl, Andrew P. Weng
Article
Oncology
Samantha J. Jones, Sumara Stroshein, Amy M. Williams, Dongmeng Liu, John J. Spinelli, Joseph M. Connors, Angela R. Brooks-Wilson
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2020)
Review
Environmental Sciences
Allan Relecom, Massimo Federico, Joseph M. Connors, Bertrand Coiffier, Irene Biasoli, Alden Moccia, Gilles Salles, Thomas McKee, Raymond Miralbell, Peter Borchmann, John Kuruvilla, Peter Johnson, Franco Cavalli, Martine Delavy, Pierre-Yves Dietrich, Antoine Flahault
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2020)
Article
Oncology
Freda M. Warner, Maryam Darvishian, Terry Boyle, Angela R. Brooks-Wilson, Joseph M. Connors, Agnes S. Lai, Nhu D. Le, Kevin Song, Heather Sutherland, Ryan R. Woods, Parveen Bhatti, John J. Spinelli
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2020)
Letter
Hematology
David D. W. Twa, Derrick G. Lee, King L. Tan, Graham W. Slack, Susana Ben-Neriah, Diego Villa, Joseph M. Connors, Laurie H. Sehn, Anja Mottok, Randy D. Gascoyne, David W. Scott, Christian Steidl, Kerry J. Savage
Editorial Material
Hematology
Joseph M. Connors
Article
Oncology
Martin Hutchings, John Radford, Stephen M. Ansell, Arpad Illes, Anna Sureda, Joseph M. Connors, Alice Sykorova, Hirohiko Shibayama, Jeremy S. Abramson, Neil S. Chua, Jonathan W. Friedberg, Jan Koren, Ann Steward LaCasce, Lysiane Molina, Gerald Engley, Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini
Summary: The study compared the efficacy and safety of different treatment regimens for Hodgkin lymphoma Stage IV patients, finding that A + AVD treatment improved PFS significantly for IV patients, with higher rates of adverse events such as peripheral neuropathy and neutropenia compared to the ABVD treatment group. In the high-risk patient subgroup, no increased incidence or severity of adverse events was observed.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Hematology
Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Summary: Treatment with R-CEOP in DLBCL patients with absolute contraindications to anthracyclines showed no significant difference in 10-year time to progression and disease-specific survival compared to the R-CHOP group, but had a lower 10-year overall survival. Therefore, R-CEOP represents a useful alternative for DLBCL patients who cannot use anthracyclines.
Article
Oncology
Dean A. Regier, Brandon Chan, Sarah Costa, David W. Scott, Christian Steidl, Joseph M. Connors, Aly Karsan, Marco A. Marra, Robert Kridel, Ian Cromwell, Samantha Pollard
Summary: This study examined the cost-effectiveness of adding ibrutinib to the treatment of patients under the age of 60 with ABC-DLBCL. The analysis found that genetic testing to diagnose ABC-DLBCL and providing ibrutinib along with standard care treatment had a low to moderate probability of being cost-effective, depending on decision maker willingness to pay and the cost of the genetic test.
Article
Hematology
Kai Zhu, Andrew Jamroz, Steven Huang, Diego Villa, Ciara L. Freeman, David W. Scott, Graham Slack, Laurie H. Sehn, Joseph M. Connors, Cynthia L. Toze, Kerry J. Savage, Alina S. Gerrie
Summary: Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) with limited information on prognostic factors and treatment approaches. In a population-based cohort from British Columbia, poor clinical outcomes were observed in the majority of HvRT patients, although those who received curative-intent therapy had similar survival rates to older patients with de novo Hodgkin lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Oncology
Andrea C. Lo, Caroline L. Holloway, Kerry J. Savage, Laurie H. Sehn, Daniel F. Worsley, Joseph M. Connors, Tom Pickles
LEUKEMIA & LYMPHOMA
(2022)
Letter
Oncology
Manik Chahal, Anna Hayden, Kerry J. Savage, Diego Villa, David W. Scott, Alina S. Gerrie, Andrea Lo, Matthew Chan, Tom Pickles, Joseph M. Connors, Laurie Helen Sehn, Ciara L. Freeman
LEUKEMIA & LYMPHOMA
(2022)
Meeting Abstract
Oncology
Shannon Healy, Daisuke Ennishi, Ali Bashashati, Saeed Saberi, Christoffer Hother, Anja Mottok, Fong Chun Chan, Lauren Chong, Robert Kridel, Merrill Boyle, Barbara Meissner, Tomohiro Aoki, Katsuyoshi Takata, Bruce W. Woolcock, Elena Vigano, Libin Abraham, Michael Gold, Adele Telenius, Pedro Farinha, Graham Slack, Susana Ben-Neriah, Daniel Lai, Allen W. Zhang, Sohrab Salehi, Hennady P. Shulha, Derek S. Chiu, Sara Mostafavi, Alina S. Gerrie, Diego Villa, Laurie H. Sehn, Kerry J. J. Savage, Andrew J. J. Mungall, Andrew P. Weng, Marcel Bally, Ryan D. Morin, Gabriela V. Cohen Freue, Joseph M. Connors, Marco A. Marra, Sohrab P. Shah, Randy D. Gascoyne, David W. Scott, Christian Steidl, Ulrich Steidl
Meeting Abstract
Oncology
David J. Straus, Monika Dlugosz-Danecka, Sergiy Alekseev, Arpad Illes, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Kerry J. Savage, Piotr Smolewski, Nancy L. Bartlett, Andrea Gallamini, Jan Andrzej Walewski, Rod Ramchandren, Pier Luigi Zinzani, Joseph M. Connors, Hina Jolin, Rachael Liu, Keenan Fenton, Michelle Fanale, John A. Radford
JOURNAL OF CLINICAL ONCOLOGY
(2019)